The global benign prostatic hyperplasia (BPH) treatment device market was valued at over $1.0 billion in 2024 and is projected to grow at a CAGR of 5.1%, reaching over $1.4 billion by 2031.
Market Segments Covered:
Transurethral Resection of the Prostate (TURP) Market
* Monopolar Electrodes
* Bipolar Electrodes
Laser BPH Market
* Holmium & Thulium Laser Equipment
* Holmium & Thulium Laser Fibers
UroLift(R) Market
Rezum(R) Market
Comprehensive Market Insights
Market Size & Growth Trends
Unit Sales & Average Selling Prices
Procedure Numbers
Market Drivers & Limiters
Forecasts Until 2031 & Historical Data (2021-2023)
Competitive Market Share Insights
Recent Mergers & Acquisitions
Company Profiles & Product Portfolios
Global BPH Treatment Device Market Trends
Pharmaceutical treatment is a key market limiter, with over 90% of BPH patients opting for drug therapy over interventional procedures in 2024.
Minimally invasive BPH treatments, such as UroLift(R) and Rezum(R), are gaining traction due to their reduced recovery time and lower risk compared to traditional surgical interventions.
Holmium & Thulium lasers are being increasingly adopted for their precision and effectiveness in tissue removal and coagulation.
Market Share Insights
Top Competitors in the Global BPH Treatment Device Market (2024):
1 Teleflex
* Market leader, with a monopoly in the UroLift(R) segment.